Sugi Predict

Sugi Predict / Compounds / SCHEMBL877412

SCHEMBL877412

SCHEMBL877412

CN(C)C(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ROCK2 O75116 14/20 0.74
▸ ROCK1 Q13464 4/20 0.63
▸ CSNK2A1 P68400 2/20 0.62
▸ STK3 Q13188 2/20 0.62
▸ AURKB Q96GD4 2/20 0.62
▸ CLK4 Q9HAZ1 2/20 0.62
▸ STK17A Q9UEE5 2/20 0.62
▸ CLK2 P49760 1/20 0.62
▸ BLK P51451 1/20 0.62
▸ DYRK1A Q13627 1/20 0.62
▸ TGFBR1 P36897 1/20 0.59
▸ KDM1A O60341 2/20 0.58
▸ PRKD3 O94806 2/20 0.57
▸ MET P08581 1/20 0.57
▸ MEN1 O00255 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ KDM4E B2RXH2 1/20 0.56
▸ MAPT P10636 1/20 0.56
▸ MAPK1 P28482 1/20 0.56
▸ ABCG2 Q9UNQ0 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3586648 0.90 ROCK2 (0.75) ROCK2ROCK1CSNK2A1STK3AURKB
SCHEMBL3795158 0.89 ROCK2 (0.66) ROCK2ROCK1CSNK2A1STK3AURKB
SCHEMBL14962652 0.88 ROCK2 (0.71) ROCK2ROCK1CSNK2A1STK3AURKB
SCHEMBL16872698 0.88 ROCK2 (0.69) ROCK2ROCK1CSNK2A1STK3AURKB
SCHEMBL882785 0.87 ROCK2 (0.74) ROCK2ROCK1CSNK2A1STK3AURKB
SCHEMBL876855 0.87 ROCK2 (0.70) ROCK2ROCK1CSNK2A1STK3AURKB
SCHEMBL1729031 0.87 ROCK2 (0.63) ROCK2ROCK1CSNK2A1STK3AURKB
SCHEMBL3794644 0.86 ROCK2 (0.67) ROCK2ROCK1CSNK2A1STK3AURKB
SCHEMBL3796260 0.86 ROCK2 (0.67) ROCK2ROCK1CSNK2A1STK3AURKB
SCHEMBL882568 0.86 ROCK2 (0.76) ROCK2ROCK1CSNK2A1STK3AURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180072710-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX INC (US) 2018-03-15 — — US claimed
EP-1865958-B1 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX INC (US) 2015-07-08 — — EP claimed
US-8916576-B2 Pharmacokinetically improved compounds SURFACE LOGIX, INC. (US) 2014-12-23 — — US claimed
US-20130131047-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX, INC. (US) 2013-05-23 — — US claimed
US-8357693-B2 Pharmacokinetically improved compounds SURFACE LOGIX, INC. (US) 2013-01-22 — — US claimed
US-20120202793-A1 RHO KINASE INHIBITORS KADMON CORPORATION, LLC 2012-08-09 — — US claimed
US-20100144707-A1 Pharmacokinetically improved compounds SURFACE LOGIX, LLC 2010-06-10 — — US claimed
US-20260034127-A1 TREATMENT OF GVHD KADMON CORP LLC (FR) 2026-02-05 — — US disclosed
EP-4116293-A2 RHO KINASE INHIBITORS Kadmon Corporation, LLC (US) 2023-01-11 — — EP disclosed
US-20220395501-A1 TREATMENT OF GVHD KADMON CORP LLC (US) 2022-12-15 — — US disclosed
EP-2903618-B1 RHO KINASE INHIBITORS KADMON CORP LLC (US) 2022-06-01 — — EP disclosed
US-11311541-B2 Treatment of GVHD KADMON CORPORATION, LLC (US) 2022-04-26 — — US disclosed
CN-113773308-A RHO kinase inhibitors 卡德门企业有限公司 2021-12-10 — — CN disclosed
WO-2012040499-A2 METABOLIC INHIBITORS SURFACE LOGIX, INC. (US) 2012-03-29 — — WO disclosed
US-20100144707-A1 Pharmacokinetically improved compounds SURFACE LOGIX, LLC 2010-06-10 — — US disclosed
US-20100144707-A1 Pharmacokinetically improved compounds SURFACE LOGIX, LLC 2010-06-10 — — US disclosed
US-20100144707-A1 Pharmacokinetically improved compounds SURFACE LOGIX, LLC 2010-06-10 — — US disclosed
WO-2008054599-A2 RHO KINASE INHIBITORS SURFACE LOGIX, INC. (US) 2008-05-08 — — WO disclosed
EP-1865958-A2 PHARMACOKINETICALLY IMPROVED COMPOUNDS Surface Logix, Inc. (US) 2007-12-19 — — EP disclosed
WO-2006105081-A2 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX, INC. (US) 2006-10-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180072710-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS ROCK2, ROCK1, RHOT2 ROCK2 1/4885ROCK1 2/4885CSNK2A1 2058/4885
US-20260034127-A1 TREATMENT OF GVHD ROCK2, RHOA, MYH2 ROCK2 1/4885ROCK1 4/4885CSNK2A1 452/4885
US-20130131047-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS ROCK2, ROCK1, RHOT2 ROCK2 1/4885ROCK1 2/4885CSNK2A1 2058/4885
US-20100144707-A1 Pharmacokinetically improved compounds ROCK2, ROCK1, RHOT2 ROCK2 1/4885ROCK1 2/4885CSNK2A1 2058/4885
US-20220395501-A1 TREATMENT OF GVHD ROCK2, ROCK1, RHOXF2 ROCK2 1/4885ROCK1 2/4885CSNK2A1 370/4885
US-11311541-B2 Treatment of GVHD ROCK2, ROCK1, RHOA ROCK2 1/4885ROCK1 2/4885CSNK2A1 438/4885
US-20120202793-A1 RHO KINASE INHIBITORS ROCK2, ROCK1, RHOA ROCK2 1/4885ROCK1 2/4885CSNK2A1 1050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.